ERBB2 and breast cancer: However, the results of the CALGB 9343 trial suggest that in women ≥70 years of age with stage I estrogen-receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative BC, the omission of surgical axillary staging does not result in worse oncologic outcomes [30].